An epidermal growth factor receptor inhibitor used to treat some cancers.
« Back to Glossary IndexNews
Related News
On May 24th, 2024, the FA Europe Network hosted its inaugural pan-European scientific meeting at the historic Saint-Louis Hospital in Paris, marking a significant milestone in international collaboration for Fanconi anemia (FA).
In this edition of our Behind the Research series, we’re excited to introduce Dr. Meng Wang, a physician-scientist at Cornell University whose work is shedding light on a little-known but powerful driver of DNA damage in Fanconi anemia: formaldehyde. Dr....
At the 2025 Fanconi Cancer Foundation Scientific Symposium in Minneapolis, the Foundation presented its Lifetime Achievement Award to Dr. John E. Wagner, MD, in recognition of his decades of groundbreaking work and unwavering commitment to improving the lives of people with Fanconi anemia (FA).